Related Experiment Video
Updated: May 7, 2026
09:34
Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells
Published on: February 9, 2019
8.4K
Formulation and evaluation of metoclopramide solid lipid nanoparticles for rectal suppository
Radwa A Mohamed1, Haidy A Abass, Mohamed A Attia
1Department of Pharmaceutical Technology, Faculty of Pharmacy and Biotechnology, German University in Cairo, GUC, Cairo, Egypt.
The Journal of Pharmacy and Pharmacology
|October 10, 2013
Summary
Metoclopramide solid lipid nanoparticles (MCP-SLNs) in suppositories offer sustained release for chemotherapy-induced nausea and vomiting. This formulation provides an effective alternative to standard metoclopramide suppositories, requiring only one dose daily.
Area of Science:
- Pharmaceutical Sciences
- Nanotechnology
- Drug Delivery Systems
Background:
- Chemotherapy often induces nausea and vomiting, necessitating effective antiemetic treatments.
- Current treatments may require multiple daily doses, impacting patient compliance.
- Solid lipid nanoparticles offer a promising approach for improved drug delivery and sustained release.
Purpose of the Study:
- To formulate and characterize metoclopramide solid lipid nanoparticles (MCP-SLNs).
- To incorporate MCP-SLNs into suppository bases for treating chemotherapy-induced nausea and vomiting.
- To evaluate the efficacy and release profile of the novel MCP-SLN suppositories for once-daily dosing.
Main Methods:
- MCP-SLNs were prepared using hot homogenization with various surfactants and concentrations.
- Formulations with high in-vitro release (>50%) were selected for suppository incorporation.
- Characterization included particle size analysis, zeta potential, and in-vivo efficacy studies compared to a market product.
Main Results:
- The optimal formulation (F9, poloxamer 407 with compritol) exhibited 80% in-vitro drug release.
- Transmission electron microscopy confirmed spherical SLN morphology with a drug-enriched core.
- MCP-SLN suppositories demonstrated comparable efficacy to market metoclopramide suppositories with a sustained release effect.
Conclusions:
- MCP-SLN suppositories effectively reverse chemotherapy-induced emesis-related gastrointestinal effects.
- The developed formulation provides a sustained release profile, enabling once-daily dosing.
- MCP-SLN suppositories represent a viable alternative to conventional metoclopramide suppositories.
Related Concept Videos
01:27Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
228
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
228
01:18Formulation and Manufacturing Process: Physical Attributes of Generic Tablets and Capsules
421
Bioequivalence in generic drugs, such as tablets and capsules, refers to their pharmaceutical equivalence to the brand-name counterparts. However, for therapeutic equivalence, manufacturers must also consider physical attributes like size, shape, and weight (FDA Guidance for Industry, December 2003). Discrepancies in these aspects could impact patient compliance and cause medication errors. For instance, swallowing difficulties, often experienced with larger tablets or capsules, can lead to...
421
01:05Bioavailability Enhancement: Drug Stability Enhancement and GI Retention
336
Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...
336
01:26Oral Drug Delivery Systems: Continuous-Release Systems
323
Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...
323
01:28Factors Influencing Drug Absorption: Pharmaceutical Parameters
836
Solid dosage forms such as tablets and capsules undergo rigorous manufacturing processes to ensure stability and effectiveness. Their dissolution and absorption properties are influenced significantly by the choice of excipients (inactive ingredients that serve various roles in the formulation), and the methodology applied during production. The manufacturing parameters, such as compression force and granulation techniques, significantly affect dissolution rates. Elevated compression forces...
836
01:27Bioavailability Enhancement: Drug Permeability Enhancement
360
After oral administration, poor permeability often limits the rate at which drugs are absorbed through the intestinal epithelium. Enhancing drug permeability is crucial for effective therapy, and several strategies have been developed to overcome this challenge.One effective strategy involves the use of lipid-based formulations. These formulations enhance dissolution and solubility, targeting physiological mechanisms to increase drug absorption. This includes stimulating bile salt secretion,...
360